A Republican bill with 4 Democratic cosponsors · See all 6 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, titled the "Delinking Revenue from Unfair Gouging Act" or the "DRUG Act," aims to improve services provided by pharmacy benefit managers. Starting January 1, 2027, it prohibits these managers from receiving remuneration for services or drug benefit administration, except for specific "bona fide service fees." These allowed fees must be flat dollar amounts and cannot be based on drug prices, discounts, or rebates. The law establishes strict enforcement through disgorgement of payments and daily civil penalties. It amends the Public Health Service Act, ERISA, and the Internal Revenue Code to implement these changes.
Yes· 3 of 6
- Scored +6
Does this lower the price of prescription medicines?
The bill aims to lower prescription drug costs by ensuring rebates and discounts are passed through to plans rather than kept as profit by PBMs.
- Scored +5
Does this give people more protection from unfair business practices?
The bill enhances consumer protection by preventing pharmacy benefit managers from using profit-driven drug pricing models.
- Scored +4
Does this lower what people pay for private health insurance?
By decoupling service fees from drug prices, the bill may lead to lower net costs for insurance issuers and plans.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Standardization of Fees: Pharmacy benefit managers can charge a "bona fide service fee," which is defined as a flat dollar amount equal to the fair market value of an actual service performed. This provides a clear and predictable way for services to be compensated (Section 2(a)(b)(1)).
-
Removal of Price-Based Incentives: The bill prevents pharmacy benefit managers from basing their compensation on drug prices, such as wholesale acquisition costs or benchmark prices. This ensures fees are not contingent upon how expensive a drug is (Section 2(a)(b)(1)(A)(i)).
-
Protection of Rebates and Discounts: The rules of construction ensure that rebates, discounts, or price concessions can still be passed through to group health plans or issuers to help lower the net costs for prescription drugs (Section 2(a)(e)(2)).
-
Accountability through Enforcement: The bill requires pharmacy benefit managers that violate the new rules to "disgorge" (give back) any improper payments received to the group health plan or insurance issuer (Section 2(a)(c)(2)).
-
Financial Penalties for Violations: To ensure compliance, the law imposes a civil monetary penalty of $10,000 for each day a violation continues (Section 2(a)(c)(3)).
Potential Negative Impacts for People
-
Restrictions on Remuneration: Starting in 2027, pharmacy benefit managers will be prohibited from deriving any remuneration from entities for services, benefit administration, or other activities related to prescription drug benefits, unless it meets the strict "bona fide service fee" exception (Section 2(a)(a)).
-
Strict Limitations on Fee Structures: Any service fee charged must be a flat dollar amount and cannot be tied to drug prices, discounts, or any other amount specified by the Secretary (Section 2(a)(b)(1)). This could limit how these entities structure their business agreements.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this lower the price of prescription medicines? — The bill aims to lower prescription drug costs by ensuring rebates and discounts are passed through to plans rather than kept as profit by PBMs. Does this lower what people pay for private health insurance? — By decoupling service fees from drug prices, the bill may lead to lower net costs for insurance issuers and plans.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Lower prescription drug costs provide financial relief to low-income households. Would middle-income households be better off under this? — Reducing the cost of prescription drugs can improve the financial stability of middle-class families.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by preventing pharmacy benefit managers from using profit-driven drug pricing models.
- Governance And Ideology
- Does this give the federal government more power? — The bill increases federal oversight and enforcement authority over pharmacy benefit managers.
- 11/4/2025
- 1 Cosponsor added.
- 3/18/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 5 Cosponsors added.
- Introduced in House
Rick AllenRepublican · Georgia
Nanette BarragánDemocrat · California
Nicole MalliotakisRepublican · New York
Donald NorcrossDemocrat · New Jersey
Bradley SchneiderDemocrat · Illinois
Shri ThanedarDemocrat · Michigan